arrow
K

Kevin O. Saunders

Duke University School of Medicine
H指数:50
被引数:9,686

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Humans and rhesus macaques share maturation pathways of HIV-1 envelope-reactive V3-glycan bnAb lineages

人类和恒河猴共享HIV-1包膜反应性V3-糖基bnAb谱系的成熟途径

2026-07-080
PRE
Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies

增强B细胞初始刺激诱导广泛中和HIV-1顶点抗体

Nature
IF48.5
2026-06-300
PRE
Mechanistic and antigenic boundaries of Henipavirus and Parahenipavirus glycoproteins

亨尼帕病毒和副亨尼帕病毒糖蛋白的机制和抗原边界

2026-06-190
OAAI
Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development

Env-antibody共进化识别B细胞初始为HIV V2顶点广谱中和抗体发展的主要瓶颈

2026-02-130
PRE
Mechanisms of early-life immunity associated with induction of heterologous HIV-1 neutralizing antibodies
2025-11-010
PRE
Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans

疫苗诱导异源HIV-1中和抗体B细胞谱系在人类中

Cell
IF42.5
2025-11-010
OAAI
Acquisition of quaternary trimer interaction as a key step in the lineage maturation of a broad and potent HIV-1 neutralizing antibody

四聚体三聚体相互作用的形成作为广谱强效HIV-1中和抗体谱系成熟过程中的关键步骤

2025-05-230
PRE
Convergence and divergence of B cell responses in two HIV-1 Env immunizations in Rhesus macaques

恒河猴中两次HIV-1 Env免疫的B细胞反应的收敛与发散

2025-05-150
OA
Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques
2024-11-270
OAAI
Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies
2024-11-030
OAAI
Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families
2024-09-181
OAAI
Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs
2024-09-171
PRE
SARS-CoV-2 Omicron XBB lineage spike structures, conformations, antigenicity, and receptor recognition
2024-07-010
OAAI
Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

非中和性SARS-CoV-2 N末端结构域抗体使用Fc介导的效应子功能保护小鼠免受严重疾病的侵害

2024-06-206
OAAI
Vaccine-mediated protection against Merbecovirus and Sarbecovirus challenge in mice
2023-10-016
OAAI
Progress in vaccine development for infectious diseases-a Keystone Symposia report

传染病疫苗开发的进展-Keystone专题讨论会报告

2023-04-054
PRE